Biogen and Eisai said their latest clinical study confirmed the amyloid hypothesis and might lead to the first drug successfully treating Alzheimer’s disease, instantly bumping their share
Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease.
The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in a dedicated headquarters for early-stage research.
